Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 1143 plus neoadjuvant carboplatin and paclitaxel in advanced epithelial ovarian cancer
2015-005137-42Phase 2Terminated
- Sponsor
- Debiopharm
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epithelial ovarian cancer (EOC) and ovarian cancer comparing Debio 1143 + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoint: Response rate. Started Feb 2016; status: terminated.
02
Drugs
xevinapant
03
Conditions
epithelial ovarian cancer (EOC)ovarian cancer
Beyond the preview
Go deeper on 2015-005137-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005137-42.